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INVITED REVIEW ARTICLE

Atrial Fibrillation Induced by Anticancer Drugs and
Underling Mechanisms
Alexander Burashnikov, PhD*†

Abstract: Cancer therapy has made major progress in the past
several decades, but treatments are often accompanied by signiﬁcant
side effects. Arrhythmias are a widespread complication of some
antineoplastic drugs, with atrial ﬁbrillation (AF) being the most often
encountered drug-associated arrhythmia. Preexisting AF risk factors
are commonly present in cancer patients who develop drugassociated AF, and active cancer itself may cause or promote AF.
Although anticancer drugs may induce AF in cancer patients without
AF risk factors, it appears that most drug-associated AF develop
when cancer drugs add or aggravate precancer-existing and/or
cancer-related pro-AF factors/alterations, additively or synergistically producing AF. Abnormalities in intracellular calcium activity
seem to be involved in the generation of anticancer drug–induced
AF. In cancer survivors with cancer therapy–induced cardiomyopathy, AF often occurs, with most of the arrhythmias likely to develop
secondary to the cardiomyopathy. AF may lead to modiﬁcation or
even cessation of cancer therapy. The management of AF in patients
with cancer is currently conducted largely based on pragmatic
assumptions. This review brieﬂy discusses AF caused by anticancer
drugs and the underlying mechanisms.
Key Words: atrial ﬁbrillation, cardio-oncology, arrhythmias, cancer
therapy
(J Cardiovasc Pharmacol Ô 2022;80:540–546)

INTRODUCTION
The treatment of patients with cancer has signiﬁcantly
improved in recent decades, largely due to the appearance of
novel anticancer therapies and early diagnosis of cancer.
However, these successful therapies are often accompanied
with signiﬁcant side effects. Cancer therapy–associated cardiovascular (CV) side effects, include cardiomyopathies,
arrhythmias, myocarditis, hypotension, and cytokine release
syndrome.1–3 The growing number of patients with serious
Received for publication September 30, 2021; accepted November 11, 2021.
From the *Lankenau Institute for Medical Research, Wynnewood, PA; and
†Sidney Kimmel College of Medicine, Thomas Jefferson University,
Philadelphia, PA.
W.W. Smith Charitable Trust.
The author reports no conﬂicts of interest.
Correspondence: Alexander Burashnikov, PhD, Lankenau Institute for
Medical Research, 100 E. Lancaster Avenue, Wynnewood, PA 19096
(e-mail: BurashnikovA@mlhs.org).
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.
0 (CCBY-NC-ND), where it is permissible to download and share the
work provided it is properly cited. The work cannot be changed in any
way or used commercially without permission from the journal.

540

| www.jcvp.org

cancer therapy–related CV complications and a better recognition of these complications led to the appearance a novel
subﬁeld in medicine in 2000–2010, called cardio-oncology.4
Cardio-oncology can be deﬁned as investigation, diagnosis,
prevention, monitoring, and treatment of CV diseases caused
or aggravated by anticancer therapy.
The occurrence of atrial ﬁbrillation (AF) in patients
with cancer is signiﬁcantly greater than that in those without
cancer when adjusted to the other confounding factors.5–9 A
greater incidence of AF is reported for patients with active
cancer and in patients with non–life-threatening cancer that
do not require active therapy.6,10 The risk of AF is highest
during the ﬁrst 3 months after cancer diagnosis.5–7 In a
Danish nationwide study, an increase in AF occurrence in
cancer patients was observed for all major types of cancer,
with lung cancer patients having the highest incidence.6
Greater AF occurrence in cancer versus noncancer patients
can be due to cancer therapy, cancer itself, and preexisting
CV comorbidities.1,2,11
It has been increasingly reported in the past 2 decades
that arrhythmias are a widespread complication of some
antineoplastic drugs, with AF being the most often encountered proarrhythmia.1,3,11–14 Data on anticancer drugassociated AF is scarce, largely coming from small, nonrandomized, and uncontrolled studies, with little or no information on AF occurrence before cancer treatment. The
absence or insufﬁcient amount of information on AF occurrence in cancer patients before treatment is a critical problem
when estimating drug-induced AF incidence. Not only may
cancer patients have a precancer AF history (reported in up to
13% of the patients9,15) but also active cancer itself appears
capable of AF induction.1,2,11 Many of the drug-related AF
cases in cancer patients are associated with the use of multiple
anticancer agents (applied simultaneously or consequently)
and with the use of the drugs following surgery,16–19 adding
to the uncertainties of AF incidence and causality.
Pharmacodynamic drug-to-drug interactions may play some
role in AF generation in patients with cancer, but this issue
has been poorly investigated.20 Postoperative AF frequently
occurs following oncological surgeries (particularly thoracic
surgeries).5,21 Such AF, however, is usually transient, appearing and disappearing within days after the surgery.21
AF in cancer patients may increase morbidity and
mortality and also result in modifying or even halting cancer
medication.1,2,14 The management of patients with cancer and
AF is poorly deﬁned. It is assumed that AF in these patients
should be generally managed similarly to that in noncancer
patients.1,2 The prime aim of the review is to discuss the
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occurrence and mechanisms of AF associated with anticancer
drugs.

AF ASSOCIATED WITH CHEMOTHERAPY
Chemotherapy is a mainstay treatment for many types
of cancer, such as breast cancer, leukemias, lymphomas, and
multiple myeloma. Although chemotherapeutic agents predominantly destroy rapidly dividing cancerous cells, they can
damage noncancerous tissues as well, including the heart. The
fact that chemotherapy can cause AF in cancer patients during
treatment was widely recognized in the ﬁrst decade of the 21st
century.11,12,22–24 AF is reported to occur in up to 10% of
patients during treatment with anthracyclines.3,11,12,25 The use
of cisplatin was associated with AF in 12%–32% of cancer
patients,3,12,23 with the highest AF incidence reported following intrapericardial infusion of cisplatin.23 Melphalan is reported to be associated with AF in 7%–22% of the patients
with cancer.12,22,24,26 Melphalan is applied as a preconditioning treatment before bone marrow transplantation in patients
with multiple myeloma.1 Bone marrow transplantation alone
does not appear to cause AF.11 In multiple studies, AF was
recorded in 0%–1.3% of cancer patients during treatment with
5-ﬂuorouracil (5-FU).27 Use of capecitabine for treating
breast cancer was associated with AF in 1.1% of patients (5
of 452).28
Anthracyclines may cause or contribute to new-onset
AF months after the end of the therapy. In a prospective
observational study involving 249 non-Hodgkin’s lymphoma
patients treated with anthracyclines, cumulatively, 15 patients
(6%) developed new-onset AF during a mean follow-up of 34
months (ECG recordings were obtained monthly).29 The ﬁrst
AF case was detected 7 months after the start of anthracycline
treatment.29
Among the chemotherapy agents, it is anthracyclines
that most often cause cardiomyopathy. Anthracyclineinduced cardiomyopathy usually develops years after anthracycline therapy, and such cardiomyopathy is likely to be a
critical causal factor of AF in cancer survivors. It was
reported that cancer survivors with anthracyclines-mediated
and nonanthracyclines-mediated cardiomyopathy had a high
prevalence of AF (56.5% and 53.1%, respectively).30

AF ASSOCIATED WITH TYROSINE KINASE
INHIBITORS (TKIs)
B-cell receptor activity is vital for the proliferation of
malignant B cells, and Bruton’s tyrosine kinase (BTK) is an
essential enzyme in the B-cell receptor signaling pathway.
The introduction of ibrutinib, a BTK inhibitor, in 2013 revolutionized the management of patients with B-cell-related
cancer types, such as chronic lymphocytic leukemia and mantle cell lymphoma,31 but AF has been observed in 6%–38% of
patients treated with ibrutinib.2,3,32,33 The relative risk of
developing AF following ibrutinib administration is reported
at 3.9–15.0.33–36 Ibrutinib has been the most prominent anticancer agent inducing AF.2,32,33,37
The second-in-class BTK inhibitor acalabrutinib was
clinically approved for the treatment of refractory or relapsed
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mantle cell lymphoma in 2017, with a warning risk for the
development of AF or atrial ﬂutter (https://www.calquence.
com). AF was observed in 7% of patients (10/134) with
relapsed/refractory lymphocytic leukemia treated with acalabrutinib for a median of 41 months.38 It appears that acalabrutinib induces AF but is less likely to do so than ibrutinib. In a
randomized controlled trial comparing zanubrutinib (a novel
BTK inhibitor) with ibrutinib, AF was observed in 2% and
15% of cancer patients (2/100 and 15/98), respectively.36
Approximately 95% of patients with chronic myeloid
leukemia (CML) have a chromosomal abnormality
(Philadelphia chromosome), resulting in the chimeric fused
oncogene BCR-ABL. BCR-ABL tyrosine kinase is critically
involved in the generation of CML, and inhibition of this
kinase causes a curative effect. Among the prominent BCRABL TKIs, ponatinib appears to be associated with AF
induction. In a randomized open-label study, AF was
recorded in 1.5% (3/155) of CML patients given ponatinib.39
The Food and Drug Administration package insert indicates
that the incidence of atrial tachyarrhythmias with ponatinib is
5%, with most cases being AF.
Angiogenesis is essential for the growth and spread of
cancerous tissue, and vascular endothelial growth factor
(VEGF) is critical for angiogenesis. Inhibition of VEGF
pathway with TKI blockers is effective in the treatment of
colorectal cancer, metastatic renal cell carcinoma, and the
like. In one study, when sorafenib was combined with 5-FU,
AF was observed in 5.1% of patients (2/39) with advanced
hepatocellular carcinoma.16 Limited available data indicate
that, when used alone, VEGF pathway inhibitors do not or
rarely induce AF.

AF ASSOCIATED WITH
PROTEASOME INHIBITORS
Proteasome inhibitors (carﬁlzomib and bortezomib)
stimulate the activation of programmed cell death in cancer
cells (via preventing the degradation of proapoptotic factors).
In a retrospective study, atrial arrhythmias (AF and atrial
tachycardia) were recorded in 7% of multiple myeloma
patients treated with carﬁlzomib (9/130).40 In a casecontrolled study, AF/atrial ﬂutter incidence was greater with
proteasome inhibitors versus controls (14% [3/21] vs. 3% [2/
75] patients, respectively).41

AF ASSOCIATED WITH HER2-TARGETED DRUGS
Overexpression of the human epidermal growth factor
receptor 2 [HER2] is signiﬁcantly involved in the development and progression of tumors in 15%–30% of patients with
breast cancer. Some patients with gastric and colon cancer
also have HER2 abnormalities. Inhibition of HER2 with trastuzumab (the ﬁrst clinically approved HER2-targeted monoclonal antibody) considerably improved the outcomes of
breast cancer patients with HER2 overexpression. The use
of trastuzumab, often adjuvant to anthracyclines, has rarely
been associated with AF (in a meta-analysis of 15 studies;
only 37 of 8124 patients [0.46%] treated with trastuzumab
were recorded with AF).42 Of note, trastuzumab is often

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

www.jcvp.org |

541

J Cardiovasc Pharmacol ä  Volume 80, Number 4, October 2022

Burashnikov

avoided in cancer patients with signiﬁcant cardiac diseases
(trastuzumab may cause or augment cardiomyopathy, particularly in adjuvant treatment to anthracyclines). When trastuzumab was applied in patients with nonlimited cardiac
comorbidity (adjuvant to anthracycline- and taxane-based
regimens), AF was recorded in 19% of patients (7/37).17

AF ASSOCIATED WITH IMMUNOTHERAPY
The prime purpose of immunotherapy in cancer patients
is to enhance or revive the ability of the immune system to
recognize and destroy cancerous tissues. Developed cancer
tumor is capable of escaping native immunity. The ﬁrst
immunotherapy used for anticancer treatment explored the
property of interleukin-2 (IL-2) to promote the expansion of
T cells (1980–1990).43 The treatment of metastatic melanoma
and renal cancer with IL-2 (aldesleukin) translated to sustainable antitumor outcomes,43 but it was associated with AF in
4.3%–8% of treated patients,44,45 among other side effects.
Lenalidomide, a multifactorial immunomodulatory agent, is
approved to treat multiple myeloma and myelodysplastic syndrome (in combination with dexamethasone). In 2 randomized and double-blinded studies, AF incidence was 2.6%
versus 0.6% (9/346 vs. 2/342) in patients treated with lenalidomide plus dexamethasone versus placebo plus dexamethasone, respectively.19
Currently, the most prominent type of anticancer
immunotherapy is immune checkpoint inhibitors (ICIs),
which are used to treat melanoma, breast cancer, colon
cancer, and the like. ICIs are monoclonal antibodies, and
they target 3 checkpoints: cytotoxic T-lymphocyte–associated
antigen-4 (CTLA-4), and programmed death receptor 1 (PD1) and its ligand (PD-L1). These checkpoints are critical for
self-tolerance, reducing the probability of autoimmune reactions. In the case of cancer, the checkpoints usually function
properly, allowing the activation of cytotoxic T cells to result
in the destruction of cancerous tissue. However, the cancer
environment may modify the checkpoints in a way that
reduces the activation of cytotoxic T cells, resulting in more
efﬁcient survival, growth, and spread of malignant tumors.
ICIs increase the probability of proper activation of the cytotoxic T cells targeting cancer, at the expense of certain side
effects. CV complications of ICI treatments are reported to
occur in 1%–5% patients and include myocarditis, pericarditis, vasculitis, and arrhythmias.46 Among patients who experience ICI-related CV cardiotoxicity, the incidence of AF was
reported to be 30% in one study (9/30 patients).47 Analyzing
and comparing CV adverse case events in patients who
received ICIs (n = 31,321) with those who received all other
drugs (n = 16,346,451) in VigiBase, the World Health
Organization’s (WHO) global database of individual case
safety reports, Salem et al found that atrial arrhythmias were
encountered signiﬁcantly more often with ICI application (in
0.71% vs. 0.42% patients, respectively).48 Considering that
ICI-induced cardiotoxicity occurs in 1%–5% patients,46 the
occurrence of ICI-associated AF seems relatively low.
Another type of immunotherapy is adoptive cell transfer (ACT), which uses genetically modiﬁed T cells derived
from the patients. Chimeric antigen receptor T cell (CAR-T)
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therapy, a subtype of ACT, signiﬁcantly improved the
treatment of hematological B-cell-related cancer, targeting
B-cell-speciﬁc CD19 that is overexpressed in B-cell malignancies. Frequent adverse effects of CAR-T therapy are
cytokine release syndrome, hypertension, and neurotoxicity.
In one study, new-onset AF was recorded in 7.5% of
hematological cancer patients treated with CAR-T (11/
145).49 In another study, 3% of patients with hematological
cancer patients (5/137) who received CAR-T developed de
novo atrial arrhythmias (3 AF or atrial ﬂutter and 2 atrial
tachycardia).15 AF was detected in 14% of patients (6/43)
with advanced stage metastatic melanoma treated with ACT
with tumor-inﬁltrating lymphocytes (TIL).50 An AF history
was recorded only in 1 of 6 patients who developed AF.50

THE OTHER ANTICANCER DRUGS AND AF
Only a portion of anticancer drugs have been associated
with the induction of AF (Table 1). Analyzing the reporting
frequency of individual cases of AF associated with anticancer drugs in the WHO case safety report database, Alexandre
et al37 identiﬁed that 19 of 176 anticancer drugs were significantly associated with AF.
There are many anticancer agents, used alone or in
combination, that have been associated with AF in case
reports and small or uncontrolled studies (such as cyclophosphamide, sunitinib, paclitaxel, imatinib, nilotinib, lapatinib,
pembrolizumab, and sorafenib + 5-FU),16 making the estimation of AF induction by these agents uncertain. The application of gemcitabine (an antimetabolite) and vemurafenib (a
BRAF kinase inhibitor) may be associated with AF induction
(as indicated in some reviews1,3,13), but the supporting published evidence does not seem to be apparent. The use of
gemcitabine in elderly patients with lung cancer was associated with AF in combination with vinorelbine (an alkaloid)
but not when applied alone (in 4/49 and 0/49 patients, respectively).51 In a study testing the safety of vemurafenib in 3226
patients with melanoma having the BRAF V600E mutation,
AF was not reported among the side effects.52
It is important to recognize that many cancer treatment
studies exclude patients with signiﬁcant CV diseases, avoiding potential side effects and thereby reducing the potential
for AF induction by cancer drugs. CV diseases are common
in patients with cancer, and some “no AF” anticancer agents
may potentially cause AF if used in cancer patients with
signiﬁcant CV diseases.

MECHANISMS OF CANCER THERAPY–
INDUCED AF
Cancer therapy induces AF by altering AF-sensitive
atrial electrophysiological parameters, directly, indirectly, or
both. For a better understanding of cancer therapy–induced
AF, it is worth brieﬂy reviewing the mechanisms underlying
AF and prime electrophysiological factors related to AF.53 AF
can be generated by abnormalities in impulse formation (ie,
focal activity) and electrical conduction (ie, reentry). AF is
initiated by focal sources, and the arrhythmia can be maintained by reentrant and focal activities.53,54 Until recently, it

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 1. Anticancer Agents Associated With AF in Patients With Cancer
Atrial Fibrillation
Anticancer Agents
Chemotherapy: anthracyclines

Chemotherapy: alkylating agents
Chemotherapy: platinum-based
agents
Tyrosine kinase inhibitors

Proteasome inhibitors
Antimetabolites
HER2 blockers
ICI therapy
ACT therapy

Immuno-modulatory agents

Doxorubicin

Active
Cancer
++

Cancer
Survivors
++*

Melphalan

++

NA

Cisplatin

++

NA

Ibrutinib
Acalabrutinib
Ponatinib
Carﬁlzomib
Bortezomib
5-ﬂuorouracil
Capecitabine
Trastuzumab§
Ipilimumab, Nivolumab,
pembrolizumab
Tisagenlecleucel, Axicabtagene
ciloleucel
ACT-TIL
Lenalidomide

+++
+
+
+
+
+
+
+
+

+†
NA
NA
NA
NA
NA
NA
NA
NA

+

NA

+
+

NA
NA

Aldesleukin (IL-2)

+

NA

Cancer Use
Breast, sarcoma, lung, bladder,
gastric, prostate, leukemia,
lymphoma
Multiple myeloma, ovarian,
neuroblastoma, SCT
Lung, bladder, testicular, breast,
esophageal, heard and neck
CCL, SLL, MCL, WM, cGVHD
CCL, SLL
CML, Ph+ ALL
Multiple myeloma
Multiple myeloma
Colon, pancreatic, breast, HNC
Breast, colon, gastric, pancreatic
Breast
Melanoma, lung, kidney, bladder,
HNC, lymphoma
B-cell acute lymphoblastic
leukemia, large B-cell lymphoma
Melanoma
Myelodysplastic syndrome,
multiple myeloma, MCL
Melanoma, renal cell carcinoma

Refs
1,12

1,12

1,12

33–35
38,‡
39
40,41
41
27
28
17
1

1

50
1,19,37

44,45

*Secondary to cancer therapy–induced cardiomyopathy.
†Ibrutinib treatment is typically indeﬁnite and may cause AF months or years after the end of active cancer symptoms.
§Seems to occur largely in patients with preexisting cardiac abnormalities.
‡https://www.calquence.com.
ACT-TIL, adoptive cell transfer with tumor inﬁltrated lymphocytes; CML, chronic myeloid leukemia; CCL, chronic lymphocytic leukemia; cGVHD, chronic graft versus host
disease; HNC, head and neck cancer; ICI, immune checkpoint inhibitor; MCL, mantle cell lymphoma; NA, not available; SCT, stem cell transplant; SLL, Small lymphocytic
lymphoma; WM, Waldenstrom’s macroglobulinemia; Ph+, ALL—Philadelphia chromosome-positive acute lymphoblastic leukemia.

was strongly believed that AF was primarily maintained by a
reentrant mechanism. However, with the improvement of
mapping technologies, increasingly more researchers either
record reentry only sporadically and short-lived or not record
it at all (for review55). Moreover, most of those who consistently record reentries during AF use the phase-mapping
approach for reentry detection that, as recently reported, has
a low speciﬁcity for identifying reentry.56 It seems the role of
reentry in the maintenance of AF is overestimated and focal
source(s) may play the leading role.55
Rapid focal sources are usually associated with intracellular calcium (Cai2+) abnormalities.53 Pharmacological
agents causing an augmentation of Cai2+ (such as isoproterenol) are known to acutely induce or promote AF.57 Among
the anticancer agents inducing AF, only doxorubicin and
ibrutinib have been tested for their effect on Cai2+, and both
have been found to produce abnormalities in cardiac Cai2+ (as
discussed later).58,59 Reentrant activities are caused by disturbances in electrical propagation of excitation.53,54 It has not
been determined if anticancer drugs inducing AF inhibit the
sodium channel (thereby producing conduction abnormalities). Yet even if they do, it does not seem to be relevant to
AF caused by drugs because sodium channel blockers typically prevent or terminate AF and do not or very rarely cause

AF de novo.55,60 Theoretically, conduction abnormalities secondary to the induction or aggravation of atrial structural
remodeling by anticancer drugs may cause or promote AF
(assuming that such conduction abnormities are more arrhythmogenic than those caused by sodium channel inhibition).
Still, if it is the case, drug-induced signiﬁcant atrial structural
remodeling is expected to develop weeks or months after the
start of treatment, and, thus, it may be relevant to AF occurring at that time but not to AF occurring within several days
of treatment. Also note that although there is a strong association between atrial structural remodeling and AF vulnerability, it is unclear if atrial structural remodeling plays a
causative or mediating role in AF generation.61 Shortening
of atrial effective refractory period (ERP) is a sensitive
marker of atrial vulnerability to AF,54,55 and pharmacological
agents shortening atrial ERP readily promote AF (such as
adenosine, acetylcholine, etc).55,60 It is unknown if anticancer
drugs associated with AF abbreviate atrial ERP.
Ibrutinib is the most prominent anticancer drug inducing AF.33,35,37 There are several experimental studies that
speciﬁcally investigated the underlying mechanisms. In neonatal rat myocytes, phosphoinositide 3-kinase (PI3K) signaling is reduced by acute application of ibrutinib, and this effect
has been proposed to contribute to the pro-AF effect of
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FIGURE 1. The more pro-AF factors and the greater their severity, the higher potential for initiation and perpetuation of drugassociated AF. Patients with active cancer who develop drug-associated AF commonly have overlapping conditions promoting AF:
anticancer drugs, cancer itself, and cardiovascular (CV) diseases (preexisting, aggravated, or induced de novo). These conditions
(separately or in a combination) may translate (directly or indirectly) to pro-AF electrophysiological alterations in the atrium,
causing AF. Most drug-associated AF in patients with active cancer appear to develop when cancer drugs add or aggravate
preexisting and/or cancer-related pro-AF factors, additively and synergistically reaching “AF threshold.”.

ibrutinib.62 PI3K regulates several ion channels (including the
sodium, potassium, and calcium channels)63 that, theoretically, may account for pro-AF effect of ibrutinib. However,
inhibition of PI3K is linked to the prolongation of cardiac
repolarization63 that is typically anti-AF not pro-AF,55 and
the use of PI3K inhibitors has not been associated with
AF,64 questioning the validity of the “PI3K hypothesis”. Of
note, ibrutinib-mediated AF commonly appears in several
months after the start of the therapy, suggesting that the
pro-AF effect of ibrutinib in cancer patients is due to chronic
rather than acute effect of the drug. It was shown recently that
a 4-week treatment of mice with ibrutinib resulted to a high
AF inducibility, left atrial enlargement, cardiac ﬁbrosis, and
myocardial inﬂammation. All were accompanied with the
inhibition of the C-terminal of Src kinase. Moreover,
cardiac-speciﬁc knockout of this kinase in mice led to AF,
left atrial enlargement, ﬁbrosis, and inﬂammation.65 These
data suggest that pro-AF effect of ibrutinib is mediated by
the inhibition of the C-terminal of Src kinase. In another
study, AF induced by 4-week treatment of ibrutinib in mice
was associated with atrial structural remodeling and abnormalities in Cai2+.58
The mechanisms of AF induced by the other anticancer
drugs have been not or much less investigated.
Anthracyclines can induce AF during the treatment,12,22–24
which may be related to a direct induction of abnormalities
in atrial Cai2+ (acute doxorubicin impairs Cai2+ in cardiac
myocytes59). Cancer survivors having anthracycline-induced
cardiomyopathy often develop AF. This arrhythmia is likely
to be commonly mediated by the cardiomyopathy.1–3 It seems
that immunotherapy agents that cause AF do so secondary to
pro-AF complications. New-onset AF in patients treated with
CAR-T and ICI therapies is strongly associated with adverse
effects (such as cytokine release syndrome15,49 and
myocarditis48).
Cancer may contribute to drug-induced AF or even
cause AF itself.11,21 Active cancer is associated with a
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number of pro-AF factors, such as systemic inﬂammation,
electrolyte and endocrine abnormalities, and stress.11,21
Among these factors, inﬂammation is believed to be the most
prominent pro-AF factor.21 Inﬂammation may induce or promote AF by altering electrophysiological parameters of the
atria directly (via dysregulation of Cai2+ handling or via alteration of ion channel function) and/or indirectly (via atrial
structural remodeling causing conduction disturbances).66
Cancer patients who develop drug-associated AF
commonly have some preexisting AF risk factors (CV
diseases, AF history, etc).11,13 Cancer agents themself may
induce or aggravate pro-AF complications (such as hypertension).1,3,11 Although anticancer drugs may cause AF in cancer
patients without AF risk factors,11,13 it seems that most of the
drug-associated AF occurring in the course of treatment
develops when cancer drugs add or exacerbate precancerexisting and/or cancer-related pro-AF factors/alterations,
reaching an “AF threshold” (Fig. 1). The risk factors for
AF associated with cancer drugs can be CV abnormalities
(hypertension, cardiomyopathy, etc), advanced age, history
of AF, stress, dosages of drugs, concomitant or prior application of other medications or therapies, and the like. These
diseases and conditions may translate (directly or indirectly
via mediators, such as inﬂammation and atrial stretch) to proAF electrophysiological alterations in the atrium (such as
abnormalities in atrial Cai2+), leading to AF generation
(Fig. 1). Notably, the greatest incidence of AF in patients
with cancer takes place during the ﬁrst several months after
cancer diagnosis,5,7 that is, when the intensity of anticancer
therapy and potency of pro-AF cancer-associated alterations
(such as inﬂammation, stress, etc) are at a maximum. Thus,
mechanisms of AF generation by anticancer agents are poorly
investigated. Alterations in atrial Cai2+ seem to be involved in
drug-induced AF. The participation of conduction disturbances in the generation of cancer drug-induced AF is uncertain. If drug-induced AF is caused by conduction
abnormalities, they are likely secondary to atrial structural

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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remodeling and not to direct inhibition of the sodium channel,
with the related AF occurring weeks or months and not days
after the start of treatment. It is important to study the effect of
anticancer agents on atrial ERP and Cai2+, which appear to be
the most relevant parameters for the estimation of druginduced AF.

MANAGEMENT OF PATIENTS WITH CANCER
AND AF
It is known that AF increases morbidity and mortality in
cancer and noncancer patients (largely due to the induction of
thromboembolism and heart failure),29,67 but the adverse
impact of AF and management of AF in cancer patients are
much less understood than in noncancer population.1–3
Among the particular concerns are that both AF and cancer
increase the risk of thromboembolism; cancer itself increases
the risk of bleeding, and some anticancer medications may
increase the risk of thromboembolism or bleeding (such as
ibrutinib, ponatinib, and lenalidomide).2,3 It is well recognized that there is a major challenge in the risk stratiﬁcation
for thromboembolism and bleeding in patients with cancer
and AF.1,2 Note, although cancer promotes arterial thromboembolism less prominently than venous thromboembolism,
the risk of the former is about double in the ﬁrst 6 months
after cancer diagnosis.68
If cancer may alter the choice of rate and rhythm
control, anticoagulation strategy, cardioversion and ablation
of AF, and appendage occlusion are poorly understood.1
There is little or no solid data-based guidelines for the management of AF in patients with cancer. It is pragmatically
assumed that the management of AF should generally be
similar for cancer and noncancer patients, with some important adjustments for cancer patients.1,2 The most recent recommendations for the management of patients with cancer
and AF are detailed in the American Heart Association statement (2021).1
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